ST. PAUL, Minn. & LAS VEGAS--(BUSINESS WIRE)--Data from Cardiovascular Systems’ (CSI) (Nasdaq: CSII) Predator 360° prospective single-center clinical study titled, Use of Orbital Treatment in a High Volume Clinical Practice Modifies Non-Compliant Plaque to Deliver Durable Long-Term Results, presented today affirmed the procedural safety and efficacy, as well as the long-term durability, of the Predator 360® PAD System in treating peripheral arterial disease (PAD), or blockages in leg arteries. The poster occurred today at the 2011 Vascular Interventional Advances (VIVA) conference.
